With recent COVID-19 spikes and rise in hospitalizations, 75% or more of hospital infection prevention efforts can be devoted to COVID-19. A new white paper authored by Sue Barnes, RN, BSN, CIC, former National Program Leader for Infection Prevention and Control for Kaiser Permanente shows MRSA colonization risk mitigation programs using Nozin Nasal Sanitizer antiseptic can be an effective response to growing healthcare-associated infection risk in the COVID-19 era. These NOVA(SM) programs are clinically proven to help reduce MRSA bacteremia infection risks up to 96%, decrease contact precautions, improve patient care, increase staff satisfaction, and save hundreds of thousands of dollars in a year.
The white paper, “Increased Risk of HAIs and the Case for Patient Decolonization in the COVID-19 Era,” discusses the success of Active Source ControlSM strategies to reduce colonization risk. It stated: “Published studies and presentations at professional symposia have shown as much as 100% elimination of MRSA surgical site infections (SSIs) following universal nasal decolonization and annualized savings per facility from $200,000 to more than $400,000.” These studies involve colonization mitigation programs that include the use of Nozin Nasal Sanitizer antiseptic.
Clinically-proven benefits of Active Source ControlSM strategies include decreased risk of HAIs, such as SSIs and central-line associated bloodstream infection (CLABSI), as well as reduced use of personal protective equipment (PPE). Hospitals are also reporting improved efficiency, cost savings and better care after adopting this program to actively decolonize patients.
As the COVID-19 pandemic accelerates innovation in hospitals to ensure patient safety, Infection Prevention departments are collaborating with hospital leadership to expedite the adoption of improved protocols to better protect everyone in the facility. Nozin introduced NOVA programs to help successfully develop and implement MRSA colonization risk mitigation, reducing the burden on staff.